D
Decipherbio
Genomic Testing for Urological Cancers
About Decipherbio
DecipherBio, a subsidiary of Veracyte, specializes in genomic testing for prostate and bladder cancers, providing actionable insights to aid in treatment decisions. Operating within the United States, DecipherBio offers its services through CLIA-validated laboratory-developed tests (LDTs), which do not require FDA clearance. The company's core clients include urologists, radiation oncologists, and other healthcare providers who treat prostate and bladder cancer patients. DecipherBio's business model revolves around offering genomic tests that help physicians assess the risk of cancer progression and tailor treatment plans accordingly. Revenue is generated through the sale of these genomic tests to healthcare providers and institutions. DecipherBio plans to expand its reach globally by adapting its genomic testing to the nCounter Analysis System, allowing for broader access to its diagnostic tools. The company operates in the genomic diagnostics market, focusing on precision medicine to improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2008
- Headquarters
- San Diego, United States
- Employees
- 84
- Open positions
- None listed
- Dealroom signal
- 25.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Urology, medical testing, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2021 | $600M | $600M | Veracyte | — |
| EARLY VCEquity / VC | Mar 2019 | $13M | $52M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Decipherbio is 2.1K monthly website visits, down 53.3% over the last three months. Decipherbio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Yonjin Venture
Other known investors3 additional known investors
Veracyte
CRG
G4A
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Decipherbio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Decipherbio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.